An FDA advisory panel narrowly recommended allowing compounding pharmacies to manufacture epitalon while voting against manufacturing emideltide. The separate, earlier decisions around other peptides brought the debate closer to broader availability for unapproved compounds, as the panel’s votes directly influence federal oversight boundaries. The advisory outcome also reflects rising scrutiny of how peptides are handled under compounding frameworks amid increased consumer interest driven by social media. For biotech and clinical stakeholders, the vote signals that “unapproved but popular” peptide requests are meeting more granular review on manufacturing and safety considerations.